Cognitive Function of Alcoholic Compensated Liver Cirrhosis

Status Completed

Clinical Trial Summary

Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis

Clinical Trial Description

Hepatic encephalopathy (HE) is one of the important complications of liver cirrhosis (LC). HE exhibits alterations in cognitive, psychomotor-intellectual, emotional, behavioral, or fine-motor functions. Approximately 22-74 % of patients with non-fulminant HE have MHE with a frequency proportional to the patient age and the severity of the liver disease. Patients with MHE exhibit disability in most functional behaviors such as social connection, alertness, emotional behavior, sleep, work, and leisure.

Alcohol consumption itself has a toxic effect on the brain. It has been documented that there is a neuronal loss in the cerebral cortex, hypothalamus, hippocampus, septal region, and cerebellum of an alcoholic brain.

The major causes of LC are hepatitis B/C viral infection and chronic alcohol consumption. The most widely accepted theory of HE pathogenesis is that toxic substances derived from the gut affect cerebral function after liver dysfunction or portosystemic shunting. This proposed pathogenetic mechanism could apply to viral compensated LC. However, it is difficult to explain the development of MHE in patients with alcoholic LC in this manner.

Therefore, patients with alcoholic LC may have different cognitive dysfunction as compared to patients with viral LC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04557774
Study type	Observational
Source	Chuncheon Sacred Heart Hospital
Contact
Status	Completed
Phase
Start date	October 1, 2011
Completion date	May 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00708617` - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease	N/A
Completed	`NCT00990639` - Effect of Candesartan in Alcoholic Liver Fibrosis	Phase 1/Phase 2
Recruiting	`NCT04106518` - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting	`NCT04666402` - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting	`NCT02331745` - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure	Phase 4
Completed	`NCT01501162` - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease	Phase 4
Recruiting	`NCT05895890` - French National MICMAF Cohort
Recruiting	`NCT03267069` - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting	`NCT03295812` - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)	N/A
Recruiting	`NCT05855031` - The Liver Care Trial	N/A
Not yet recruiting	`NCT03503708` - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease	N/A
Completed	`NCT02796469` - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT02140294` - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease	N/A
Recruiting	`NCT03209791` - Ethanol Induces Skeletal Muscle Autophagy
Recruiting	`NCT04736966` - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Phase 1
Recruiting	`NCT04400604` - Study of Alcohol-related Liver Disease in Europe
Completed	`NCT03402256` - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients	N/A
Completed	`NCT01711125` - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease	Phase 3
Active, not recruiting	`NCT03863730` - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota	N/A
Not yet recruiting	`NCT06307964` - Intra-Hepatic Microbiota in Alcoholic Hepatitis